AB001 / Agastiya Biotech - LARVOL DELTA

EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS (EHA 2023) - "Asciminib, also known as ABL001, could transform the standard of care in this population through its novel mechanism of action of specifically targeting the ABL myristoyl pocket (STAMP) inhibitor... According to a previous study, individuals in CML who do not experience an early molecular response to imatinib will likely have worse outcomes...Asciminib inhibited CML cells and ponatinib resistance in a dose-dependent manner... VK2 and asciminib are suggested as a novel approach for treatment of ABL-TKI-resistant cells since they increase treatment efficacy. Additionally, VK2 may also have a positive effect for CML patients infected with COVID-19. COVID-19, Asciminib, Chronic myeloid leukemia"

Chronic Myeloid Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Osteoporosis • Rheumatology • CASP3 • CASP7 • IL1B

Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for Pancreatic cancer and Acute Myeloid Leukemia (AML) (PRNewswire) - "Agastiya Biotech and Vopec Pharmaceuticals announce that the US FDA has granted Orphan Drug Designations for Pancreatic Cancer and AML for its novel small molecule, AB001....AB001 is a small molecule PD-L1 checkpoint inhibitor that also targets aberrant intracellular signaling pathways in the tumor microenvironment, such as Wnt/beta-catenin, PI3K, and RAS."

Orphan drug • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Oncology • Pancreatic Cancer